All News
All News


A share purchase agreement was signed on 05 April 2024 to transfer the majority of our company's shares to Curium International Trading B.V.

As Eczacıbaşı-Monrol, we have been collaborating with Curium – , a world leader in nuclear medicine that develops, manufactures and distributes world-class radiopharmaceutical products to help patients around the globe – for the production of Lu-177 at Curium's Petten facility in the Netherlands since 2022. This acquisition decision is a natural evolution of the strong partnership between both companies.

In its 8 April press release, Curium emphasized that the acquisition will bring together complementary geographical footprints and advanced Lu-177 production capabilities, PET & SPECT nuclear medicine infrastructure, fostering the development of innovative radionuclides and radiopharmaceuticals, and stated, “It is expected that this strategic move significantly boost Curium's Lu-177 manufacturing capacity to address the rising global demand, benefiting over 100,000 critically ill patients in the next five years. Additionally, the inclusion of Eczacıbaşı-Monrol’s manufacturing and logistics infrastructure will further strengthen Curium’s integrated production and distribution capabilities.”

We believe the joint vision of both companies to provide hope to patients in their treatment will add significant value to all of our stakeholders and the healthcare ecosystem. Moreover the agreement will bring together highly complementary geographical footprints and infrastructure of both companies focused on nuclear medicine – supporting cutting-edge radionuclides and radiopharmaceuticals pipelines for diagnostic and therapeutic purposes.

We also want to reassure that it is business as usual at Eczacıbaşı-Monrol for work and relationships with our production, facilities, product deliveries, customers and other stakeholders. Subject to fulfilment of regulatory approvals and other conditions, we expect that the transaction to close within 2024. Everyone at Eczacıbaşı-Monrol remains focused on our day-to-day activities to deliver the same high quality products and high standards of service our partners expect.

We look forward to sharing with you the new developments and our joint plans with Curium that will occur in the future.

other news